Board of Directors
Colin joined Shell International in Den Haag and served in the group’s worldwide operations. He held executive positions within the French group TOTAL in strategic planning and development economics and at Mobil, where he was a member of the Management Council, Vice President and Director overseeing the business, scientific and technical service directorates at Mobil Gas Marketing and Mobil North Sea.
After the Millennium, in his mid-forties, he changed direction and worked extensively across the public service and not-for-profit sectors, including in local government, environment, education, health, social care, justice and prison reform. He was Chief Executive at the Chief Fire Officers Association under the Bain reform of the UK Fire & Rescue Service where he was advisor to the President of the ministerial sounding board, and was also Chief Executive at the National Open College Network.
Colin was Chief Executive at the national mutual Benenden Healthcare and Hospital Group, founded in 1905 for patients suffering tuberculosis unable to meet cost of long term care, then of early influence in founding National Insurance and the NHS. As part of that role, he was a director delegate member of the Association Internationale de la Mutualité, an international umbrella organisation of not-for-profit healthcare federations procuring or providing medical coverage to around 240 million people across Europe, Latin America, Africa and the Middle East.
He has also been external Executive Business Advisor to the Environment Agency under UK Treasury, Office of Government Commerce programme to leverage international treaty objectives for air, water and ground quality through the introduction of enabling technology.
Colin is appointed Oxford Martin Visiting Fellow, on the Affordable Medicines research programme, University of Oxford, through support of the Structural Genomics Consortium at the Nuffield Department of Clinical Medicine.
He was appointed Alan Tayler Advisory Fellow (Mathematics) by the University of Oxford where he is also advisor to the directors of the joint EPSRC Centre for Doctoral Training, industrially focused mathematical modelling programme at the Mathematics Institute. He is also board advisor to the joint MRC & EPSRC Centre for Doctoral Training, systems approaches to biomedical science, University of Oxford.
He is invited as independent chair at Harwell campus Accelerator Development Board, an embryonic scale up partnership between the Science & Technology Facilities Council and Oxford Academic Health Science Network.
With a continued interest in earth sciences and environmental protection Colin advises the Oxford Climate Policy body and the Nekton Deep Ocean Institute scientific expedition missions. He has been a guest lecturer in geoscience engineering at the University of Aberdeen and led an inaugural post graduate external mentorship programme at the Kuala Lumpur Business School, University of Nottingham Malaysia Campus.
He is Chair of the medical biotech company EnteroBiotix focussed on using the body’s microorganisms to prevent and treat debilitating infections and disease. Colin is also Chairman at the community interest company EuroBiotix CiC formed to promote research in to the human microbiota and expand safe access to faecal microbiota transplantation.
Colin holds other board positions at the Shakespeare Birthplace Trust and also in biodiversity and international community conservation with The Wallacea Trust focussed around worldwide scientific data collection and expedition sites of Operation Wallacea.
Dr James McIlroy is a practicing NHS doctor and the Founder of EnteroBiotix, one of Europe’s leading microbiome companies
He started the EnteroBiotix as a 21-year-old medical student in his Mum and Dad’s garden shed. He built the Company alongside his studies: raising over £2m in seed funding, hosting a visit from the First Minister/Chief Medical Officer and establishing several NHS and EU based hospital partnerships. As CEO, he led the Company became the first in the world to secure a license from the Medicines and Healthcare Products Regulatory Agency (MHRA) to manufacture microbial products derived from faecal donations. Following this.success, EnteroBiotix began distributing its first medicinal products internationally and the Company is now opening offices in Boston and Paris in 2019.
He holds an Honours degree in Physiology from the University of Edinburgh and a degree in Medicine (MBChB) from the University of Aberdeen, graduating with a distinction and the Elective Prize in Child Health. After graduating, he was appointed as Honorary Lecturer in Healthcare Innovation to The School of Medicine, Medical Sciences and Nutrition. His main research interest is the role and influence of gut bacteria in the pathogenesis and management of intestinal and extra-intestinal disease. He has presented work at over ten national/international conferences and has published serval first author peer reviewed articles and book chapters in journals such as Alimentary Pharmacology and Therapeutics.
He is a Founding Member of the next-generation advisory committee at Opportunity North East, a privately held regional development agency founded by Sir Ian Wood that is focussed on stimulating economic renaissance in the North East of Scotland. He is also Orator at Robert Gordon’s College and Co-Founder of EthosBio CIC, an organisation established to embed socially impactful entrepreneurship within the life-sciences sector.
James has won a number of awards for his entrepreneurial endeavours. He was named ‘Young Innovator of the Year’ by Herald Scotland and ‘Entrepreneur of the Year’ by Business Quarter Magazine. In 2016, he was awarded an Enterprise Fellowship by the Royal Society of Edinburgh. In 2017, he was awarded a Visiting Research Fellowship by United European Gastroenterology.
James is a seasoned biotechnology c-level executive with an extensive track record of creating value in biotechnology business ventures. He was previously VP of Clinical Laboratory Operations at Inivata, a global cancer genomics company that is developing products to support cancer diagnosis. His previous roles include Chief Technology Officer at Enterome, a Paris-based microbiome company with advanced technology and products, Vice President of Research and Development at MDxHealth SA, and Chief Operating Officer at Response Genetics (IPO:NASDAQ).
James has raised over $100m in private and public placements and has significant experience in building and managing high performance teams in the biotechnology sector. He has been first author or co-author in a number of high-profile peer reviewed academic papers in journals such as Nature Genetics.
Lewis Ritchie is James Mackenzie Professor of General Practice at the University of Aberdeen. He holds honorary Professorships at the Universities of Edinburgh and the Highlands and Islands (UHI), and is an honorary Consultant in Public Health Medicine with NHS Grampian. He is currently Chair of the Queen’s Nursing Institute Scotland and previously held posts as Principal General Practitioner Peterhead Health Centre and Community Hospital and as Director of Public Health NHS Grampian.
Gavin is Managing Director of Marlin Bioconsulting Limited, and an experienced life sciences licensing and business development professional. His previous roles include Vice President of Business Development for Tibotec-Virco NV and Commercial Director of Phares Technology BV. At GSK, he was responsible for Global Licensing Infectious Diseases, and held senior marketing and commercial management posts with Novartis, Bayer and Janssen. He co-founded novel class antibiotic company MGB Biopharma in 2009 and currently represents the investment interests of Scottish Enterprise as Non-Executive Director at Lamellar Biomedical Limited.
Gavin serves on the advisory board of the Scottish Lifesciences Association, is an Enterprise partner at University of Strathclyde and is a Certified Licensing Professional as accredited by the Licensing Executives Society (USA and Canada).
Through her thirty year career, Carol has held a range of global HR Director roles within Investment Banking and high growth Technology businesses in London, Amsterdam and Edinburgh. She has led teams that have supported business strategy and change within international businesses, working alongside C-suite and Board level decision makers. Carol continues her career advising, mainly SME’s, whilst running her hypnotherapy business. She is a Fellow of the Institute of Personnel & Development.Carol is a member of both Equity Gap and Par Equity, Scottish business angel syndicates.